Sanara MedTech Inc.
sanaramedtech.comWhat Do They Do?
Sells surgical soft-tissue repair and bone-fusion products to hospitals and surgical centers for use by surgeons in operating rooms.
10-K for FY2025, filed Mar 24, 2026
How Do They Make Money?
Customers place purchase orders for products at agreed prices; Sanara earns revenue when the products are delivered.
10-K for FY2025, filed Mar 24, 2026Customer purchase orders are generally considered to be contracts under ASC 606. Purchase orders typically identify the specific terms of…View ↗
The Company has established prices for its products. These prices are effectively agreed to when customers place purchase orders with the…View ↗
Product revenues are recognized when a purchase order is received from the customer, the products are delivered, and control of the goods…View ↗
-
10-K for FY2025, filed Mar 24, 2026
FY2025 revenue by product or service ↗
$103.1M
-
10-K for FY2025, filed Mar 24, 2026
$103.1M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Soft Tissue Repair Products
Sold outright
10-K for FY2025, filed Mar 24, 2026 |
89%
FY2022: 91%
|
Soft Tissue Repair Products, FY2025
$91.3M Sources
|
Sold outright |
|
Bone Fusion Products
Sold outright
10-K for FY2025, filed Mar 24, 2026 |
11%
FY2022: 8.7%
|
Bone Fusion Products, FY2025
$11.8M Sources
|
Sold outright |
Who Are Their Customers?
Sanara markets products to surgeons at hospitals and surgical centers, selling through surgical specialty distributors and company representatives.
10-K for FY2025, filed Mar 24, 2026
Do Revenues Turn Into Profits?
Not on paper. It lost $37.6M in FY2025, but brought in more cash than it spent: $2.2M of free cash flow.
10-K for FY2025, filed Mar 24, 2026
$7.3MView ↗
10-K for FY2025, filed Mar 24, 2026
−$37.6MView ↗
10-K for FY2025, filed Mar 24, 2026
$2.2MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$452.9KView ↗
- ▼ −78% (Loss)
- vs −$2M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 11, 2026
Open tableView ↗
-
Sep 30, 2026
Shareholders approved the MiMedx merger
The merger remains subject to required regulatory approvals and other conditions.
Sources
8-K, filed Oct 1, 2026
A proposal to approve and adopt the Agreement and Plan of Merger, dated as of July 29, 2026 (as it may be amended, supplemented, waived or…View ↗
-
Jul 29, 2026
MiMedx agreed to acquire Sanara
The transaction would give Sanara shareholders cash and MiMedx shares and remains subject to shareholder, regulatory and other conditions.
Sources
8-K, filed Jul 29, 2026
On July 29, 2026, Sanara MedTech Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among…View ↗
Growing. Revenue grew 4.3x in 4 years, from $24.1M in FY2021 to $103.1M in FY2025, about 44% a year.
Narrower market focus
The older report described products, services and technologies spanning surgical, chronic wound and skincare care, including virtual consultations and diagnostics. The latest report says the company discontinued its post-acute wound-care program and is focusing exclusively on surgical products and technologies.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Mar 24, 2026We are a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and…View ↗
Our comprehensive solution consists of four key components: diagnostics, virtual consult services for wound care and dermatology…View ↗
Our WounDerm technology-based services include an EMR software platform for both wound and skin conditions, wound and skin virtual consult…View ↗
Loading...
